Qiagen reported fourth-quarter earnings of $0.62 per share, matching the Zacks Consensus Estimate and narrowly trailing the $0.64 per share posted in the prior-year period. Revenue rose 3% year-over-year to $460 million, driven by strength in molecular diagnostics and sample preparation consumables. Adjusted operating margin expanded by 120 basis points to 28.5%, reflecting disciplined cost management and manufacturing efficiency gains in Germany and the United States.

Total kit and consumable sales grew 5% year-over-year, outperforming the Street’s 4% growth forecast, while instrument sales slipped 2%, slightly underperforming the anticipated flat result. Molecular diagnostics revenue climbed 6%, led by robust demand for pathogen detection assays in Europe, where volume increased by 15%. Clinical workflow automation offerings showed order growth of 12% externally but installation delays weighted on instrument revenue recognition.

At SLAS 2026 in Boston, Qiagen unveiled QIAsprint Connect, a benchtop system capable of processing up to 192 samples per run with a touch-based interface and modular chemistry. Consumables packaging volume has been cut by 40% and plastic usage by half. Management forecasts that automation solutions will contribute 10% of total revenue by year-end, up from 7% at December 31, 2025, as labs worldwide adopt high-throughput workflows.

Qiagen reiterated its full-year guidance for mid‐single-digit revenue growth and adjusted EPS of $2.50–$2.60, assuming currency headwinds of approximately 150 basis points. R&D spending is expected to increase by 8% to support next-generation sequencing panel launches in Q3, while free cash flow conversion is projected at 85%. Investors will watch for quarterly order trends in automation platforms and margin leverage from manufacturing footprint consolidation.